Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab

Sema4 Press Release | 12.17.20

Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab

Merus and Sema4 are utilizing Sema4’s genomic testing to identify patients with tumors harboring neuregulin 1 gene fusions who may be eligible for investigational treatment with the bispecific antibody Zenocutuzumab in a trial sponsored by Merus.